drugset
drugset / Trial / NCT01229865

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

NCT01229865 ↗

Phase 2 Completed 29 enrolled Vascular Biogenics Ltd. operating as VBL Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.

Timeline

Start
2010-12
Primary completion
2014-10
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject VB-111 Other / unclassified — —

Indications

differentiated thyroid carcinoma